Showing results (41-50 of 252) with videos related to
Sort By:
Pageof 26
The Oncologist|July 12, 2011
Cardiovascular toxicity profiles of vascular-disrupting agentsIshwaria M Subbiah, Daniel J Lenihan, Apostolia M TsimberidouJournal of the American College of Cardiology|August 3, 2019
From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5)Darryl P Leong, John J V McMurray, Philip G Joseph, et al.JACC. Basic to Translational Science|July 18, 2019
Emerging Therapeutics for the Treatment of Light Chain and Transthyretin AmyloidosisKathleen W Zhang, Keith E Stockerl-Goldstein, Daniel J LenihanThe American Journal of Medicine|January 25, 2022
Developing Therapy for Transthyretin AmyloidosisCourtney M Campbell, Kathleen Zhang, Daniel J Lenihan, et al.Cancer|May 23, 2013
Cardiac toxicity in cancer survivorsDaniel J Lenihan, Stefano Oliva, Eric J Chow, et al.European Heart Journal|August 12, 2025
Cardiovascular biomarkers for risk stratification in primary preventionJohannes T Neumann, James A de Lemos, Fred S Apple, et al.JACC. Cardiooncology|January 13, 2025
Cardiovascular Risk in Prostate Cancer: JACC: CardioOncology State-of-the-Art ReviewDarryl P Leong, Avirup Guha, Alicia K Morgans, et al.Current Cardiology Reports|July 27, 2023
Diagnosis and Management of Cardiovascular Effects of Bruton's Tyrosine Kinase InhibitorsNazanin Aghel, Rocio C Baro Vila, Michelle Lui, et al.Heart Failure Clinics|September 30, 2018
Management of Cancer Therapeutics-Related Cardiac DysfunctionAjay Vallakati, Bhavana Konda, Daniel J Lenihan, et al.American Journal of Physiology. Heart and Circulatory Physiology|January 11, 2003
Evidence for association of coronary sinus levels of hepatocyte growth factor and collateralization in human coronary diseaseDaniel J Lenihan, Abdulfatah Osman, Vissa Sriram, et al.Pageof 26